Emerging evidence indicates that unfavorable intermediate risk (UIR) and high-risk prostate tumors (IUSP grade ≥3) exhibit approximately 20% cumulative incidence of PSMA-detected intraprostatic local relapse following 45 Gy 5-fraction primary SABR (18). The gene discussed is FOLH1; the disease is prostate neoplasm.